Intravesical Therapy for Non-muscle Invasive Bladder Cancer-Current and Future Options in the Age of Bacillus Calmette-Guerin Shortage

Overview

Journal Rev Urol

Date 2020 Feb 20

PMID 32071562

Citations 8

Authors

Vishnukamal Golla

Andrew T Lenis

Izak Faiena

Karim Chamie

Affiliations

Soon will be listed here.

Abstract

Non-muscle invasive bladder cancer (NMIBC) is a common and burdensome malignancy. A substantial proportion of patients with intermediate- and high-risk disease will progress to invasive bladder cancer and are at a significant risk for metastasis and death. Bacillus Calmette-Guerin (BCG) therapy for selected cases has been the standard of care for nearly 40 years. Unfortunately, a world-wide shortage has made BCG challenging to obtain. Furthermore, recurrences and progressions do occur. With the US Food and Drug Administration creating a clear path to drug approval for novel treatments, many therapies have been tested, including intravesical cytotoxic chemotherapy, intravesical immunotherapy, systemic immunotherapy, and novel agents, such as gene therapy and targeted therapy. In this review, we highlight ongoing clinical trials.

Citing Articles

Diminished Short-Term Efficacy of Reduced-Dose Induction BCG in the Treatment of Non-Muscle Invasive Bladder Cancer.

Ostrowski D, Chelluri R, Herzig M, Xia L, Cortese B, Roberson D Cancers (Basel). 2023; 15(14).

PMID: 37509407 PMC: 10377836. DOI: 10.3390/cancers15143746.

Prospective observational study of the role of the microbiome in BCG responsiveness prediction (SILENT-EMPIRE): a study protocol.

Bieri U, Scharl M, Sigg S, Szczerba B, Morsy Y, Ruschoff J BMJ Open. 2022; 12(4):e061421.

PMID: 35437256 PMC: 9016396. DOI: 10.1136/bmjopen-2022-061421.

Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).

Broughton E, Gooden K, Mycock K, Rajkovic I, Taylor-Stokes G BMC Urol. 2022; 22(1):27.

PMID: 35219307 PMC: 8882282. DOI: 10.1186/s12894-022-00959-z.

Mycobacterium bovis bacille Calmette-Guerin-derived extracellular vesicles as an alternative to live BCG immunotherapy.

Gellings P, Galeas-Pena M, Morici L Clin Exp Med. 2022; 23(2):519-527.

PMID: 35076789 DOI: 10.1007/s10238-022-00794-4.

Spinal Tuberculosis Secondary to Intravesical Bacille Calmette-Guerin Treatment for Bladder Cancer.

Yergin C, Pafford R, Pirris J, Rao D, Rahmathulla G Cureus. 2021; 13(8):e17446.

PMID: 34589352 PMC: 8460556. DOI: 10.7759/cureus.17446.

References

Herr H, Sogani P . Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol. 2001; 166(4):1296-9. View

Wrangle J, Velcheti V, Patel M, Garrett-Mayer E, Hill E, Ravenel J . ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018; 19(5):694-704. PMC: 6089612. DOI: 10.1016/S1470-2045(18)30148-7. View

Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S . Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. 2006; 56(8):1173-82. PMC: 11029839. DOI: 10.1007/s00262-006-0266-z. View

Donin N, Lenis A, Holden S, Drakaki A, Pantuck A, Belldegrun A . Immunotherapy for the Treatment of Urothelial Carcinoma. J Urol. 2016; 197(1):14-22. DOI: 10.1016/j.juro.2016.02.3005. View

Mathios D, Park C, Marcus W, Alter S, Rhode P, Jeng E . Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int J Cancer. 2015; 138(1):187-94. PMC: 4696021. DOI: 10.1002/ijc.29686. View

Liu B, Jones M, Kong L, Noel T, Jeng E, Shi S . Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Cytokine. 2018; 107:105-112. PMC: 5916319. DOI: 10.1016/j.cyto.2017.12.003. View

Chang S, Boorjian S, Chou R, Clark P, Daneshmand S, Konety B . Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016; 196(4):1021-9. DOI: 10.1016/j.juro.2016.06.049. View

Mostafid A, Porta N, Cresswell J, Griffiths T, Kelly J, Penegar S . CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. BJU Int. 2020; 125(6):817-826. PMC: 7318672. DOI: 10.1111/bju.15038. View

Karsh L, Shore N, Soloway M, Bhat G, Reddy G, Leu S . Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola™) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2018; 4(3):293-301. PMC: 6087454. DOI: 10.3233/BLC-180166. View

10.

Messing E . The BCG Shortage. Bladder Cancer. 2017; 3(3):227-228. PMC: 5545921. DOI: 10.3233/BLC-179018. View

11.

Belldegrun A, Franklin J, ODonnell M, Gomella L, Klein E, Neri R . Superficial bladder cancer: the role of interferon-alpha. J Urol. 1998; 159(6):1793-801. DOI: 10.1016/S0022-5347(01)63160-4. View

12.

Chamie K, Saigal C, Lai J, Hanley J, Setodji C, Konety B . Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer. 2011; 117(23):5392-401. PMC: 3206145. DOI: 10.1002/cncr.26198. View

13.

Madeb R, Golijanin D, Noyes K, Fisher S, Stephenson J, Long S . Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer. 2009; 115(12):2660-70. PMC: 2769205. DOI: 10.1002/cncr.24311. View

14.

Lenis A, Donin N, Litwin M, Saigal C, Lai J, Hanley J . Association Between Number of Endoscopic Resections and Utilization of Bacillus Calmette-Guérin Therapy for Patients With High-Grade, Non-Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer. 2016; 15(1):e25-e31. PMC: 5183565. DOI: 10.1016/j.clgc.2016.06.014. View

15.

Luca S, Mihaescu T . History of BCG Vaccine. Maedica (Bucur). 2013; 8(1):53-8. PMC: 3749764. View

16.

Sylvester R, van der Meijden A, Oosterlinck W, Witjes J, Bouffioux C, Denis L . Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006; 49(3):466-5. DOI: 10.1016/j.eururo.2005.12.031. View

17.

Boehm B, Svatek R . Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer. Urol Clin North Am. 2015; 42(2):159-68, vii. DOI: 10.1016/j.ucl.2015.02.001. View

18.

. 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018. J Immunother Cancer. 2018; 6(Suppl 1):115. PMC: 6220479. DOI: 10.1186/s40425-018-0423-x. View

19.

Velaer K, Steinberg R, Thomas L, ODonnell M, Nepple K . Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer. Curr Urol Rep. 2016; 17(5):38. DOI: 10.1007/s11934-016-0594-2. View

20.

Maruf M, Brancato S, Agarwal P . Nonmuscle invasive bladder cancer: a primer on immunotherapy. Cancer Biol Med. 2016; 13(2):194-205. PMC: 4944546. DOI: 10.20892/j.issn.2095-3941.2016.0020. View